Clinical Trial

Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer

Study acronym: PREOPANC-3
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The PREOPANC-3 study is a randomized, multicenter, phase 3 trial. Patients with resectable pancreatic cancer will be randomly assigned (1:1) to 8 cycles of neoadjuvant mFOLFIRINOX followed by surgery and 4 cycles of adjuvant mFOLFIRINOX (arm 1) or to upfront surgery followed by 12 cycles of adjuvant mFOLFIRINOX (arm 2). The primary objective of the trial is to determine whether perioperative mFOLFIRINOX improves overall survival compared with adjuvant mFOLFIRINOX in patients with resectable pancreatic cancer.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2021-06-15; most recent amendment 2026-05-13.
Status change: Recruiting → Active, Not Recruiting 2026-05-13
Status change: Not Yet Recruiting → Recruiting 2021-09-07
Trial Details
NCT Number NCT04927780
Lead Sponsor Erasmus Medical Center
Collaborators: Dutch Pancreatic Cancer Group, Dutch Cancer Society
Conditions Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma
Enrollment 378 participants
Start Date 2021-09-07
Primary Completion 2027-01 (estimated)
Study Completion 2029-07 (estimated)
Updated on ClinicalTrials.gov 2026-05-15